CA2579242A1 - Sulfonamides and uses thereof - Google Patents

Info

Publication number

CA2579242A1

CA2579242A1 CA002579242A CA2579242A CA2579242A1 CA 2579242 A1 CA2579242 A1 CA 2579242A1 CA 002579242 A CA002579242 A CA 002579242A CA 2579242 A CA2579242 A CA 2579242A CA 2579242 A1 CA2579242 A1 CA 2579242A1

Authority

CA

Canada

Prior art keywords

compound

independently

alkyl

formula

heteroaryl

Prior art date

2004-09-27

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 229940124530 sulfonamide Drugs 0.000 title description 15
• 150000003456 sulfonamides Chemical class 0.000 title description 2
• 150000001875 compounds Chemical class 0.000 claims abstract description 320
• 238000000034 method Methods 0.000 claims abstract description 66
• 125000000217 alkyl group Chemical group 0.000 claims description 56
• -1 cyclylalkyl Chemical group 0.000 claims description 53
• 125000000623 heterocyclic group Chemical group 0.000 claims description 43
• 125000003118 aryl group Chemical group 0.000 claims description 38
• 125000001072 heteroaryl group Chemical group 0.000 claims description 34
• 208000008589 Obesity Diseases 0.000 claims description 31
• 235000020824 obesity Nutrition 0.000 claims description 30
• 229910052739 hydrogen Inorganic materials 0.000 claims description 29
• 239000001257 hydrogen Substances 0.000 claims description 28
• 125000004122 cyclic group Chemical group 0.000 claims description 24
• 125000003342 alkenyl group Chemical group 0.000 claims description 23
• 125000003545 alkoxy group Chemical group 0.000 claims description 19
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
• 125000000304 alkynyl group Chemical group 0.000 claims description 18
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 17
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
• 125000004432 carbon atom Chemical group C* 0.000 claims description 15
• 125000005843 halogen group Chemical group 0.000 claims description 15
• 229910052757 nitrogen Inorganic materials 0.000 claims description 15
• 125000005842 heteroatom Chemical group 0.000 claims description 14
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 13
• 125000001188 haloalkyl group Chemical group 0.000 claims description 13
• 125000001424 substituent group Chemical group 0.000 claims description 13
• 206010012601 diabetes mellitus Diseases 0.000 claims description 11
• 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 11
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
• 125000004043 oxo group Chemical group O=* 0.000 claims description 7
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
• 229910020008 S(O) Inorganic materials 0.000 claims description 6
• 229910052799 carbon Inorganic materials 0.000 claims description 6
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
• 208000001145 Metabolic Syndrome Diseases 0.000 claims description 5
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 5
• 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 5
• 108020004021 3-ketosteroid receptors Proteins 0.000 claims description 4
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
• 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 4
• 125000003282 alkyl amino group Chemical group 0.000 claims description 4
• 125000004438 haloalkoxy group Chemical group 0.000 claims description 4
• 125000004995 haloalkylthio group Chemical group 0.000 claims description 4
• 229910052736 halogen Inorganic materials 0.000 claims description 4
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
• 150000002825 nitriles Chemical class 0.000 claims description 4
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
• 238000006467 substitution reaction Methods 0.000 claims description 4
• 229910052717 sulfur Inorganic materials 0.000 claims description 4
• 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
• 125000005018 aryl alkenyl group Chemical group 0.000 claims description 3
• 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 3
• 125000005015 aryl alkynyl group Chemical group 0.000 claims description 3
• 125000004104 aryloxy group Chemical group 0.000 claims description 3
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
• 150000002367 halogens Chemical group 0.000 claims description 3
• 108020000002 NR3 subfamily Proteins 0.000 claims description 2
• 125000006350 alkyl thio alkyl group Chemical group 0.000 claims description 2
• 125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 2
• 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 2
• 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 2
• 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims description 2
• 150000002431 hydrogen Chemical group 0.000 claims 8
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
• 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 2
• 229910052760 oxygen Inorganic materials 0.000 claims 2
• 102100022631 Glutamate receptor ionotropic, NMDA 2C Human genes 0.000 claims 1
• 125000001475 halogen functional group Chemical group 0.000 claims 1
• 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
• 108091008646 testicular receptors Proteins 0.000 claims 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 117
• 102000000393 Ghrelin Receptors Human genes 0.000 description 113
• 108010016122 Ghrelin Receptors Proteins 0.000 description 113
• 208000035475 disorder Diseases 0.000 description 96
• 230000000694 effects Effects 0.000 description 73
• 108010051696 Growth Hormone Proteins 0.000 description 67
• 102000018997 Growth Hormone Human genes 0.000 description 67
• 239000000122 growth hormone Substances 0.000 description 67
• 238000011282 treatment Methods 0.000 description 50
• 102100033367 Appetite-regulating hormone Human genes 0.000 description 43
• 101800001586 Ghrelin Proteins 0.000 description 43
• 210000004027 cell Anatomy 0.000 description 43
• GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 43
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 38
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 35
• 239000005557 antagonist Substances 0.000 description 34
• 206010028980 Neoplasm Diseases 0.000 description 32
• 239000000203 mixture Substances 0.000 description 31
• 108090000623 proteins and genes Proteins 0.000 description 31
• 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 30
• 239000000556 agonist Substances 0.000 description 30
• 210000001519 tissue Anatomy 0.000 description 28
• 239000000463 material Substances 0.000 description 22
• 201000010099 disease Diseases 0.000 description 21
• 230000001613 neoplastic effect Effects 0.000 description 21
• 102000004169 proteins and genes Human genes 0.000 description 20
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 19
• 102000004877 Insulin Human genes 0.000 description 19
• 108090001061 Insulin Proteins 0.000 description 19
• 238000003556 assay Methods 0.000 description 19
• 239000008103 glucose Substances 0.000 description 19
• 229940125396 insulin Drugs 0.000 description 19
• 235000018102 proteins Nutrition 0.000 description 19
• 208000024891 symptom Diseases 0.000 description 18
• 241000282414 Homo sapiens Species 0.000 description 17
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 17
• 241001465754 Metazoa Species 0.000 description 15
• 230000003247 decreasing effect Effects 0.000 description 14
• 241000699670 Mus sp. Species 0.000 description 13
• 210000004369 blood Anatomy 0.000 description 13
• 239000008280 blood Substances 0.000 description 13
• 230000001965 increasing effect Effects 0.000 description 13
• 238000004519 manufacturing process Methods 0.000 description 13
• 208000024172 Cardiovascular disease Diseases 0.000 description 12
• 201000010769 Prader-Willi syndrome Diseases 0.000 description 12
• 150000001413 amino acids Chemical class 0.000 description 12
• 235000013305 food Nutrition 0.000 description 12
• 235000002639 sodium chloride Nutrition 0.000 description 12
• 201000011510 cancer Diseases 0.000 description 11
• 239000002552 dosage form Substances 0.000 description 11
• 230000001225 therapeutic effect Effects 0.000 description 11
• 201000009030 Carcinoma Diseases 0.000 description 10
• 102000016267 Leptin Human genes 0.000 description 10
• 108010092277 Leptin Proteins 0.000 description 10
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 10
• 229940039781 leptin Drugs 0.000 description 10
• 210000004072 lung Anatomy 0.000 description 10
• 208000030159 metabolic disease Diseases 0.000 description 10
• 230000011664 signaling Effects 0.000 description 10
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 9
• 206010022489 Insulin Resistance Diseases 0.000 description 9
• 230000027455 binding Effects 0.000 description 9
• 229940125425 inverse agonist Drugs 0.000 description 9
• 239000008194 pharmaceutical composition Substances 0.000 description 9
• 150000003839 salts Chemical class 0.000 description 9
• 210000002784 stomach Anatomy 0.000 description 9
• 206010006895 Cachexia Diseases 0.000 description 8
• 102000038455 IGF Type 1 Receptor Human genes 0.000 description 8
• 108010031794 IGF Type 1 Receptor Proteins 0.000 description 8
• 206010033307 Overweight Diseases 0.000 description 8
• 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 8
• 229940024606 amino acid Drugs 0.000 description 8
• 239000003937 drug carrier Substances 0.000 description 8
• 238000002347 injection Methods 0.000 description 8
• 239000007924 injection Substances 0.000 description 8
• 230000001404 mediated effect Effects 0.000 description 8
• 230000002503 metabolic effect Effects 0.000 description 8
• 230000004060 metabolic process Effects 0.000 description 8
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 8
• 208000015122 neurodegenerative disease Diseases 0.000 description 8
• 235000020825 overweight Nutrition 0.000 description 8
• 230000001105 regulatory effect Effects 0.000 description 8
• 210000002027 skeletal muscle Anatomy 0.000 description 8
• 210000000813 small intestine Anatomy 0.000 description 8
• 238000001356 surgical procedure Methods 0.000 description 8
• 238000012360 testing method Methods 0.000 description 8
• 206010019280 Heart failures Diseases 0.000 description 7
• 208000012902 Nervous system disease Diseases 0.000 description 7
• 235000001014 amino acid Nutrition 0.000 description 7
• 230000036528 appetite Effects 0.000 description 7
• 235000019789 appetite Nutrition 0.000 description 7
• 239000011324 bead Substances 0.000 description 7
• 239000000872 buffer Substances 0.000 description 7
• 230000002496 gastric effect Effects 0.000 description 7
• 230000007823 neuropathy Effects 0.000 description 7
• 201000001119 neuropathy Diseases 0.000 description 7
• 208000033808 peripheral neuropathy Diseases 0.000 description 7
• 230000028327 secretion Effects 0.000 description 7
• 239000002904 solvent Substances 0.000 description 7
• 238000003786 synthesis reaction Methods 0.000 description 7
• 238000011830 transgenic mouse model Methods 0.000 description 7
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
• 206010007559 Cardiac failure congestive Diseases 0.000 description 6
• 241000124008 Mammalia Species 0.000 description 6
• 241000700159 Rattus Species 0.000 description 6
• 208000009956 adenocarcinoma Diseases 0.000 description 6
• 210000000593 adipose tissue white Anatomy 0.000 description 6
• 125000002619 bicyclic group Chemical group 0.000 description 6
• 230000037396 body weight Effects 0.000 description 6
• 210000000481 breast Anatomy 0.000 description 6
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
• 235000019197 fats Nutrition 0.000 description 6
• 210000002216 heart Anatomy 0.000 description 6
• 210000000936 intestine Anatomy 0.000 description 6
• 210000004185 liver Anatomy 0.000 description 6
• 230000036210 malignancy Effects 0.000 description 6
• 238000012544 monitoring process Methods 0.000 description 6
• 125000002950 monocyclic group Chemical group 0.000 description 6
• 230000009826 neoplastic cell growth Effects 0.000 description 6
• 210000000496 pancreas Anatomy 0.000 description 6
• 238000002360 preparation method Methods 0.000 description 6
• 230000002265 prevention Effects 0.000 description 6
• 102000005962 receptors Human genes 0.000 description 6
• 108020003175 receptors Proteins 0.000 description 6
• 230000019491 signal transduction Effects 0.000 description 6
• 230000007958 sleep Effects 0.000 description 6
• 239000007787 solid Substances 0.000 description 6
• 239000000725 suspension Substances 0.000 description 6
• 239000003981 vehicle Substances 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• 102000011690 Adiponectin Human genes 0.000 description 5
• 108010076365 Adiponectin Proteins 0.000 description 5
• 208000019901 Anxiety disease Diseases 0.000 description 5
• 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 5
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
• 101710151321 Melanostatin Proteins 0.000 description 5
• 102400000064 Neuropeptide Y Human genes 0.000 description 5
• 206010054048 Postoperative ileus Diseases 0.000 description 5
• 206010060862 Prostate cancer Diseases 0.000 description 5
• 102000007156 Resistin Human genes 0.000 description 5
• 108010047909 Resistin Proteins 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• 102000013275 Somatomedins Human genes 0.000 description 5
• 230000005856 abnormality Effects 0.000 description 5
• 230000001154 acute effect Effects 0.000 description 5
• 210000000577 adipose tissue Anatomy 0.000 description 5
• 239000002671 adjuvant Substances 0.000 description 5
• 206010064930 age-related macular degeneration Diseases 0.000 description 5
• 238000010171 animal model Methods 0.000 description 5
• 230000036506 anxiety Effects 0.000 description 5
• 230000015572 biosynthetic process Effects 0.000 description 5
• 210000004556 brain Anatomy 0.000 description 5
• 239000003153 chemical reaction reagent Substances 0.000 description 5
• 230000001684 chronic effect Effects 0.000 description 5
• 210000001072 colon Anatomy 0.000 description 5
• 238000002474 experimental method Methods 0.000 description 5
• 230000004634 feeding behavior Effects 0.000 description 5
• 238000009472 formulation Methods 0.000 description 5
• 230000030136 gastric emptying Effects 0.000 description 5
• 230000012010 growth Effects 0.000 description 5
• 208000002780 macular degeneration Diseases 0.000 description 5
• 230000007257 malfunction Effects 0.000 description 5
• 108020004999 messenger RNA Proteins 0.000 description 5
• 210000005170 neoplastic cell Anatomy 0.000 description 5
• URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 5
• 108090000765 processed proteins & peptides Proteins 0.000 description 5
• 230000000069 prophylactic effect Effects 0.000 description 5
• 210000002307 prostate Anatomy 0.000 description 5
• 238000011084 recovery Methods 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 239000011347 resin Substances 0.000 description 5
• 229920005989 resin Polymers 0.000 description 5
• 230000004044 response Effects 0.000 description 5
• 239000000243 solution Substances 0.000 description 5
• 210000001875 somatotroph Anatomy 0.000 description 5
• 208000011580 syndromic disease Diseases 0.000 description 5
• 238000013518 transcription Methods 0.000 description 5
• 230000035897 transcription Effects 0.000 description 5
• 230000004584 weight gain Effects 0.000 description 5
• 235000019786 weight gain Nutrition 0.000 description 5
• 206010006187 Breast cancer Diseases 0.000 description 4
• 208000026310 Breast neoplasm Diseases 0.000 description 4
• 208000017667 Chronic Disease Diseases 0.000 description 4
• 102000004315 Forkhead Transcription Factors Human genes 0.000 description 4
• 108090000852 Forkhead Transcription Factors Proteins 0.000 description 4
• 206010020710 Hyperphagia Diseases 0.000 description 4
• 102000057413 Motilin receptors Human genes 0.000 description 4
• 108700040483 Motilin receptors Proteins 0.000 description 4
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
• 208000026214 Skeletal muscle atrophy Diseases 0.000 description 4
• 102000005157 Somatostatin Human genes 0.000 description 4
• 108010056088 Somatostatin Proteins 0.000 description 4
• 108050001286 Somatostatin Receptor Proteins 0.000 description 4
• 102000011096 Somatostatin receptor Human genes 0.000 description 4
• 210000004100 adrenal gland Anatomy 0.000 description 4
• 230000002776 aggregation Effects 0.000 description 4
• 238000004220 aggregation Methods 0.000 description 4
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
• 210000003295 arcuate nucleus Anatomy 0.000 description 4
• 125000004429 atom Chemical group 0.000 description 4
• 235000012000 cholesterol Nutrition 0.000 description 4
• 230000002950 deficient Effects 0.000 description 4
• 239000002270 dispersing agent Substances 0.000 description 4
• 230000002708 enhancing effect Effects 0.000 description 4
• 238000011156 evaluation Methods 0.000 description 4
• 230000037406 food intake Effects 0.000 description 4
• 235000012631 food intake Nutrition 0.000 description 4
• 230000006870 function Effects 0.000 description 4
• 239000004615 ingredient Substances 0.000 description 4
• 210000003734 kidney Anatomy 0.000 description 4
• 230000014759 maintenance of location Effects 0.000 description 4
• 230000015654 memory Effects 0.000 description 4
• 206010061289 metastatic neoplasm Diseases 0.000 description 4
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
• 230000004770 neurodegeneration Effects 0.000 description 4
• 102000039446 nucleic acids Human genes 0.000 description 4
• 108020004707 nucleic acids Proteins 0.000 description 4
• 150000007523 nucleic acids Chemical class 0.000 description 4
• 239000004031 partial agonist Substances 0.000 description 4
• 230000001817 pituitary effect Effects 0.000 description 4
• 229920001223 polyethylene glycol Polymers 0.000 description 4
• 108010040003 polyglutamine Proteins 0.000 description 4
• 239000000651 prodrug Substances 0.000 description 4
• 229940002612 prodrug Drugs 0.000 description 4
• 210000002966 serum Anatomy 0.000 description 4
• 230000007781 signaling event Effects 0.000 description 4
• 230000025185 skeletal muscle atrophy Effects 0.000 description 4
• NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 4
• 229960000553 somatostatin Drugs 0.000 description 4
• 210000000278 spinal cord Anatomy 0.000 description 4
• 210000000952 spleen Anatomy 0.000 description 4
• 230000000638 stimulation Effects 0.000 description 4
• 210000001685 thyroid gland Anatomy 0.000 description 4
• 210000004291 uterus Anatomy 0.000 description 4
• 230000001515 vagal effect Effects 0.000 description 4
• QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 3
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
• 102000054930 Agouti-Related Human genes 0.000 description 3
• 101710127426 Agouti-related protein Proteins 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
• 241000282326 Felis catus Species 0.000 description 3
• 102100020948 Growth hormone receptor Human genes 0.000 description 3
• 206010053759 Growth retardation Diseases 0.000 description 3
• 239000007995 HEPES buffer Substances 0.000 description 3
• 241000725303 Human immunodeficiency virus Species 0.000 description 3
• 102000000589 Interleukin-1 Human genes 0.000 description 3
• 108010002352 Interleukin-1 Proteins 0.000 description 3
• 208000027747 Kennedy disease Diseases 0.000 description 3
• 208000017170 Lipid metabolism disease Diseases 0.000 description 3
• 208000002569 Machado-Joseph Disease Diseases 0.000 description 3
• 241000699666 Mus <mouse, genus> Species 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• 208000018737 Parkinson disease Diseases 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• 208000006265 Renal cell carcinoma Diseases 0.000 description 3
• 206010039491 Sarcoma Diseases 0.000 description 3
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
• 108010068542 Somatotropin Receptors Proteins 0.000 description 3
• 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 3
• 102400000096 Substance P Human genes 0.000 description 3
• 101800003906 Substance P Proteins 0.000 description 3
• 102000019197 Superoxide Dismutase Human genes 0.000 description 3
• 108010012715 Superoxide dismutase Proteins 0.000 description 3
• 238000010521 absorption reaction Methods 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 239000002585 base Substances 0.000 description 3
• 230000009286 beneficial effect Effects 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 208000029742 colonic neoplasm Diseases 0.000 description 3
• 208000029078 coronary artery disease Diseases 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 230000004064 dysfunction Effects 0.000 description 3
• 239000012636 effector Substances 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 235000021588 free fatty acids Nutrition 0.000 description 3
• 230000014509 gene expression Effects 0.000 description 3
• 231100000001 growth retardation Toxicity 0.000 description 3
• 150000002430 hydrocarbons Chemical group 0.000 description 3
• 238000000338 in vitro Methods 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 230000031891 intestinal absorption Effects 0.000 description 3
• 230000004068 intracellular signaling Effects 0.000 description 3
• 239000003446 ligand Substances 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 238000012423 maintenance Methods 0.000 description 3
• 235000012054 meals Nutrition 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 230000037323 metabolic rate Effects 0.000 description 3
• 230000001394 metastastic effect Effects 0.000 description 3
• GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 3
• 210000003205 muscle Anatomy 0.000 description 3
• 210000002569 neuron Anatomy 0.000 description 3
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
• 210000001672 ovary Anatomy 0.000 description 3
• 239000002245 particle Substances 0.000 description 3
• 239000008188 pellet Substances 0.000 description 3
• 235000021317 phosphate Nutrition 0.000 description 3
• 229920000155 polyglutamine Polymers 0.000 description 3
• 238000000159 protein binding assay Methods 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 239000007790 solid phase Substances 0.000 description 3
• 239000000126 substance Substances 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 238000001890 transfection Methods 0.000 description 3
• 150000003626 triacylglycerols Chemical class 0.000 description 3
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• MGSNWNLPMHXGDD-DFWOJPNQSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2r)-6-amino-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]hexanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CC=1NC=NC=1)C1=CC=CC=C1 MGSNWNLPMHXGDD-DFWOJPNQSA-N 0.000 description 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
• MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
• PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 2
• 208000030507 AIDS Diseases 0.000 description 2
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
• 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
• 108010000239 Aequorin Proteins 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• 208000000044 Amnesia Diseases 0.000 description 2
• 102000007371 Ataxin-3 Human genes 0.000 description 2
• 102000007368 Ataxin-7 Human genes 0.000 description 2
• 108010032953 Ataxin-7 Proteins 0.000 description 2
• 206010003694 Atrophy Diseases 0.000 description 2
• 206010061666 Autonomic neuropathy Diseases 0.000 description 2
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• 208000029402 Bulbospinal muscular atrophy Diseases 0.000 description 2
• 208000032841 Bulimia Diseases 0.000 description 2
• 206010006550 Bulimia nervosa Diseases 0.000 description 2
• 208000031229 Cardiomyopathies Diseases 0.000 description 2
• 102000000844 Cell Surface Receptors Human genes 0.000 description 2
• 108010001857 Cell Surface Receptors Proteins 0.000 description 2
• 206010009944 Colon cancer Diseases 0.000 description 2
• 229920002261 Corn starch Polymers 0.000 description 2
• 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 2
• 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 2
• 229920000858 Cyclodextrin Polymers 0.000 description 2
• 201000008163 Dentatorubral pallidoluysian atrophy Diseases 0.000 description 2
• 206010051153 Diabetic gastroparesis Diseases 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• 208000032928 Dyslipidaemia Diseases 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 208000030814 Eating disease Diseases 0.000 description 2
• 208000019454 Feeding and Eating disease Diseases 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101000915806 Homo sapiens Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B beta isoform Proteins 0.000 description 2
• 208000031226 Hyperlipidaemia Diseases 0.000 description 2
• 206010021518 Impaired gastric emptying Diseases 0.000 description 2
• 208000026350 Inborn Genetic disease Diseases 0.000 description 2
• 208000032382 Ischaemic stroke Diseases 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
• 206010027476 Metastases Diseases 0.000 description 2
• 206010028289 Muscle atrophy Diseases 0.000 description 2
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
• 206010033128 Ovarian cancer Diseases 0.000 description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
• 241000009328 Perro Species 0.000 description 2
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• 208000033766 Prolymphocytic Leukemia Diseases 0.000 description 2
• 208000017442 Retinal disease Diseases 0.000 description 2
• 206010038923 Retinopathy Diseases 0.000 description 2
• 102100029014 Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B beta isoform Human genes 0.000 description 2
• 208000020221 Short stature Diseases 0.000 description 2
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
• 208000024313 Testicular Neoplasms Diseases 0.000 description 2
• 208000037063 Thinness Diseases 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
• 230000001594 aberrant effect Effects 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 201000006966 adult T-cell leukemia Diseases 0.000 description 2
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
• 230000029936 alkylation Effects 0.000 description 2
• 238000005804 alkylation reaction Methods 0.000 description 2
• DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 208000022531 anorexia Diseases 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 239000007900 aqueous suspension Substances 0.000 description 2
• 206010003119 arrhythmia Diseases 0.000 description 2
• 210000001367 artery Anatomy 0.000 description 2
• 230000037444 atrophy Effects 0.000 description 2
• 230000002238 attenuated effect Effects 0.000 description 2
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
• 150000005347 biaryls Chemical group 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 230000036765 blood level Effects 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 230000001925 catabolic effect Effects 0.000 description 2
• 238000001516 cell proliferation assay Methods 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• 208000020832 chronic kidney disease Diseases 0.000 description 2
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
• 230000027288 circadian rhythm Effects 0.000 description 2
• 239000008120 corn starch Substances 0.000 description 2
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 206010061428 decreased appetite Diseases 0.000 description 2
• 230000008021 deposition Effects 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 208000037765 diseases and disorders Diseases 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 239000006274 endogenous ligand Substances 0.000 description 2
• 238000006911 enzymatic reaction Methods 0.000 description 2
• 201000010063 epididymitis Diseases 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 description 2
• 235000019439 ethyl acetate Nutrition 0.000 description 2
• 230000029142 excretion Effects 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 150000004665 fatty acids Chemical class 0.000 description 2
• 229910052731 fluorine Inorganic materials 0.000 description 2
• 125000002541 furyl group Chemical group 0.000 description 2
• 230000030135 gastric motility Effects 0.000 description 2
• 208000001288 gastroparesis Diseases 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 208000016361 genetic disease Diseases 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 230000000762 glandular Effects 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 239000003862 glucocorticoid Substances 0.000 description 2
• 125000005456 glyceride group Chemical group 0.000 description 2
• 230000003394 haemopoietic effect Effects 0.000 description 2
• 201000009277 hairy cell leukemia Diseases 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 230000003054 hormonal effect Effects 0.000 description 2
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
• 206010020718 hyperplasia Diseases 0.000 description 2
• 230000002267 hypothalamic effect Effects 0.000 description 2
• 210000003016 hypothalamus Anatomy 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 238000003018 immunoassay Methods 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 238000005462 in vivo assay Methods 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• 229960000367 inositol Drugs 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 208000017169 kidney disease Diseases 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 230000003902 lesion Effects 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• 230000037356 lipid metabolism Effects 0.000 description 2
• 239000006193 liquid solution Substances 0.000 description 2
• 208000014018 liver neoplasm Diseases 0.000 description 2
• 210000004324 lymphatic system Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 201000001441 melanoma Diseases 0.000 description 2
• NYXHSRNBKJIQQG-UHFFFAOYSA-N methyl n-methylcarbamate Chemical compound CNC(=O)OC NYXHSRNBKJIQQG-UHFFFAOYSA-N 0.000 description 2
• 230000020763 muscle atrophy Effects 0.000 description 2
• 201000000585 muscular atrophy Diseases 0.000 description 2
• 230000035772 mutation Effects 0.000 description 2
• 201000005962 mycosis fungoides Diseases 0.000 description 2
• 208000010125 myocardial infarction Diseases 0.000 description 2
• 210000005036 nerve Anatomy 0.000 description 2
• 230000001537 neural effect Effects 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 239000000346 nonvolatile oil Substances 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 210000004789 organ system Anatomy 0.000 description 2
• 150000002894 organic compounds Chemical class 0.000 description 2
• 230000008520 organization Effects 0.000 description 2
• VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
• 210000003800 pharynx Anatomy 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• 230000036470 plasma concentration Effects 0.000 description 2
• 229920000136 polysorbate Polymers 0.000 description 2
• 230000002980 postoperative effect Effects 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 125000006239 protecting group Chemical group 0.000 description 2
• 150000003254 radicals Chemical class 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• 239000003488 releasing hormone Substances 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 229920006395 saturated elastomer Polymers 0.000 description 2
• 230000000580 secretagogue effect Effects 0.000 description 2
• 208000019116 sleep disease Diseases 0.000 description 2
• 230000003860 sleep quality Effects 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
• 229960001052 streptozocin Drugs 0.000 description 2
• 230000035882 stress Effects 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
• 239000004094 surface-active agent Substances 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 230000002194 synthesizing effect Effects 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• 125000001544 thienyl group Chemical group 0.000 description 2
• 125000005309 thioalkoxy group Chemical group 0.000 description 2
• 235000021476 total parenteral nutrition Nutrition 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 238000000844 transformation Methods 0.000 description 2
• 230000009261 transgenic effect Effects 0.000 description 2
• 210000004881 tumor cell Anatomy 0.000 description 2
• 206010048828 underweight Diseases 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• 238000005303 weighing Methods 0.000 description 2
• 230000029663 wound healing Effects 0.000 description 2
• 238000013293 zucker diabetic fatty rat Methods 0.000 description 2
• ZTQSJWKZYQJWLP-XUXLGOTHSA-N (2s)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[(2-amino-2-methylpropanoyl)amino]-3-(4h-imidazol-4-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)C(C)(N)C)C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1C=NC=N1 ZTQSJWKZYQJWLP-XUXLGOTHSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• HKWJHKSHEWVOSS-OMDJCSNQSA-N 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4-bisphosphate) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O HKWJHKSHEWVOSS-OMDJCSNQSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• 102000004899 14-3-3 Proteins Human genes 0.000 description 1
• 101710112812 14-3-3 protein Proteins 0.000 description 1
• CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
• FPFHGANFLADRPU-UHFFFAOYSA-N 2-(diethylamino)-N-[1-(6-methyl-[1,2,4]triazolo[4,3-a]pyridin-3-yl)-2-phenylmethoxyethyl]ethanesulfonamide Chemical compound CCN(CC)CCS(=O)(=O)NC(COCc1ccccc1)c1nnc2ccc(C)cn12 FPFHGANFLADRPU-UHFFFAOYSA-N 0.000 description 1
• YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
• 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
• WHNPOQXWAMXPTA-UHFFFAOYSA-N 3-methylbut-2-enamide Chemical compound CC(C)=CC(N)=O WHNPOQXWAMXPTA-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 208000004611 Abdominal Obesity Diseases 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 206010000599 Acromegaly Diseases 0.000 description 1
• HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 208000009304 Acute Kidney Injury Diseases 0.000 description 1
• 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
• 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
• 102100036664 Adenosine deaminase Human genes 0.000 description 1
• 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
• 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
• 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 201000003076 Angiosarcoma Diseases 0.000 description 1
• 206010003162 Arterial injury Diseases 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 102000007372 Ataxin-1 Human genes 0.000 description 1
• 108010032963 Ataxin-1 Proteins 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 102100035656 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Human genes 0.000 description 1
• 108010001478 Bacitracin Proteins 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• 208000006373 Bell palsy Diseases 0.000 description 1
• 206010004593 Bile duct cancer Diseases 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 108010051479 Bombesin Proteins 0.000 description 1
• 102000013585 Bombesin Human genes 0.000 description 1
• 208000010392 Bone Fractures Diseases 0.000 description 1
• 208000006386 Bone Resorption Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• 108010074051 C-Reactive Protein Proteins 0.000 description 1
• 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
• 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
• DSVOIXRZVNWZES-UHFFFAOYSA-N CCN(CC)C1CCC(C1)S(=O)(=O)NC(COCc1ccccc1)c1nnc2CC(COC(=O)NC)CCn12 Chemical compound CCN(CC)C1CCC(C1)S(=O)(=O)NC(COCc1ccccc1)c1nnc2CC(COC(=O)NC)CCn12 DSVOIXRZVNWZES-UHFFFAOYSA-N 0.000 description 1
• 101100322915 Caenorhabditis elegans akt-1 gene Proteins 0.000 description 1
• 101100162366 Caenorhabditis elegans akt-2 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
• 201000000274 Carcinosarcoma Diseases 0.000 description 1
• 208000002177 Cataract Diseases 0.000 description 1
• 102000003908 Cathepsin D Human genes 0.000 description 1
• 108090000258 Cathepsin D Proteins 0.000 description 1
• 206010065941 Central obesity Diseases 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 208000005243 Chondrosarcoma Diseases 0.000 description 1
• 201000009047 Chordoma Diseases 0.000 description 1
• 208000006332 Choriocarcinoma Diseases 0.000 description 1
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 101800000414 Corticotropin Proteins 0.000 description 1
• 229920000742 Cotton Polymers 0.000 description 1
• 208000009798 Craniopharyngioma Diseases 0.000 description 1
• 241000938605 Crocodylia Species 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 208000014311 Cushing syndrome Diseases 0.000 description 1
• 102000004030 Cyclin G2 Human genes 0.000 description 1
• 108090000487 Cyclin G2 Proteins 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 150000008574 D-amino acids Chemical class 0.000 description 1
• 230000007067 DNA methylation Effects 0.000 description 1
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
• 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
• 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
• 108010049003 Fibrinogen Proteins 0.000 description 1
• 102000008946 Fibrinogen Human genes 0.000 description 1
• 208000001640 Fibromyalgia Diseases 0.000 description 1
• 201000008808 Fibrosarcoma Diseases 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 206010070531 Foetal growth restriction Diseases 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• 102000054184 GADD45 Human genes 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 102000004862 Gastrin releasing peptide Human genes 0.000 description 1
• 108090001053 Gastrin releasing peptide Proteins 0.000 description 1
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
• 229930182566 Gentamicin Natural products 0.000 description 1
• 208000008069 Geographic Atrophy Diseases 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 208000002705 Glucose Intolerance Diseases 0.000 description 1
• 239000004366 Glucose oxidase Substances 0.000 description 1
• 108010015776 Glucose oxidase Proteins 0.000 description 1
• 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
• 208000001258 Hemangiosarcoma Diseases 0.000 description 1
• 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
• SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 108700014808 Homeobox Protein Nkx-2.2 Proteins 0.000 description 1
• 101000803294 Homo sapiens BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Proteins 0.000 description 1
• 101001066158 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 alpha Proteins 0.000 description 1
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
• 101000836394 Homo sapiens Sestrin-1 Proteins 0.000 description 1
• 101000664887 Homo sapiens Superoxide dismutase [Cu-Zn] Proteins 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 208000037171 Hypercorticoidism Diseases 0.000 description 1
• 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 208000019025 Hypokalemia Diseases 0.000 description 1
• 206010021118 Hypotonia Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 206010022680 Intestinal ischaemia Diseases 0.000 description 1
• 206010056457 Intra-abdominal haematoma Diseases 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• 150000008575 L-amino acids Chemical class 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 1
• 208000018142 Leiomyosarcoma Diseases 0.000 description 1
• 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 238000000134 MTT assay Methods 0.000 description 1
• 231100000002 MTT assay Toxicity 0.000 description 1
• 241000282560 Macaca mulatta Species 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000007054 Medullary Carcinoma Diseases 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 101800002739 Melanin-concentrating hormone Proteins 0.000 description 1
• 208000004535 Mesenteric Ischemia Diseases 0.000 description 1
• 206010027406 Mesothelioma Diseases 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 108091092878 Microsatellite Proteins 0.000 description 1
• 208000036769 Mild mental retardation Diseases 0.000 description 1
• 208000019022 Mood disease Diseases 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 101100460498 Mus musculus Nkx2-2 gene Proteins 0.000 description 1
• 208000007379 Muscle Hypotonia Diseases 0.000 description 1
• 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 208000028389 Nerve injury Diseases 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• 102100038813 Neuromedin-U Human genes 0.000 description 1
• 101710138657 Neurotoxin Proteins 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 206010029748 Noonan syndrome Diseases 0.000 description 1
• 238000000636 Northern blotting Methods 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 201000010133 Oligodendroglioma Diseases 0.000 description 1
• 102000002512 Orexin Human genes 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 208000004286 Osteochondrodysplasias Diseases 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
• 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
• 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
• 208000018262 Peripheral vascular disease Diseases 0.000 description 1
• 102000017343 Phosphatidylinositol kinases Human genes 0.000 description 1
• 108050005377 Phosphatidylinositol kinases Proteins 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 208000007641 Pinealoma Diseases 0.000 description 1
• 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
• 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 206010062519 Poor quality sleep Diseases 0.000 description 1
• 102100033721 Pro-MCH Human genes 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 102000007327 Protamines Human genes 0.000 description 1
• 108010007568 Protamines Proteins 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 108091008611 Protein Kinase B Proteins 0.000 description 1
• 238000011530 RNeasy Mini Kit Methods 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 108070000025 Releasing hormones receptors Proteins 0.000 description 1
• 102000016983 Releasing hormones receptors Human genes 0.000 description 1
• 208000033626 Renal failure acute Diseases 0.000 description 1
• 108091027981 Response element Proteins 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 206010058360 Retroperitoneal haematoma Diseases 0.000 description 1
• 206010050404 Retroperitoneal infection Diseases 0.000 description 1
• 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
• 238000011831 SOD1-G93A transgenic mouse Methods 0.000 description 1
• 102000004531 Selenoprotein P Human genes 0.000 description 1
• 108010042443 Selenoprotein P Proteins 0.000 description 1
• 201000010208 Seminoma Diseases 0.000 description 1
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
• 102100027288 Sestrin-1 Human genes 0.000 description 1
• 206010072610 Skeletal dysplasia Diseases 0.000 description 1
• 206010068771 Soft tissue neoplasm Diseases 0.000 description 1
• 208000007107 Stomach Ulcer Diseases 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
• 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 description 1
• 208000026216 Thoracic disease Diseases 0.000 description 1
• 208000026928 Turner syndrome Diseases 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 102000014384 Type C Phospholipases Human genes 0.000 description 1
• 108010079194 Type C Phospholipases Proteins 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 206010046543 Urinary incontinence Diseases 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 206010047228 Venous injury Diseases 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 208000014070 Vestibular schwannoma Diseases 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
• 241000269370 Xenopus <genus> Species 0.000 description 1
• ZSZXYWFCIKKZBT-ZVDPZPSOSA-N [(2r)-3-[[(2s,3s,5r,6s)-2,6-dihydroxy-3,4,5-triphosphonooxycyclohexyl]oxy-hydroxyphosphoryl]oxy-2-hexadecanoyloxypropyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OC1[C@H](O)[C@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O ZSZXYWFCIKKZBT-ZVDPZPSOSA-N 0.000 description 1
• INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 1
• BOKJXLVCRZDWQA-UHFFFAOYSA-N [3-[1-[(1-methylpiperidin-4-yl)sulfonylamino]-2-phenylmethoxyethyl]-[1,2,4]triazolo[4,3-a]pyridin-5-yl]methyl 3-hydroxypyrrolidine-1-carboxylate Chemical compound CN1CCC(CC1)S(=O)(=O)NC(COCc1ccccc1)c1nnc2cccc(COC(=O)N3CCC(O)C3)n12 BOKJXLVCRZDWQA-UHFFFAOYSA-N 0.000 description 1
• IKJQSFCPHSYCKO-UHFFFAOYSA-N [3-[1-[[3-(diethylamino)cyclobutyl]sulfonylamino]-2-phenylmethoxyethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl]methyl N-methylcarbamate Chemical compound CCN(CC)C1CC(C1)S(=O)(=O)NC(COCc1ccccc1)c1nnc2CC(COC(=O)NC)CCn12 IKJQSFCPHSYCKO-UHFFFAOYSA-N 0.000 description 1
• NVDCCPJZDUJEGP-UHFFFAOYSA-N [3-[1-[[3-(diethylamino)cyclobutyl]sulfonylamino]-2-phenylmethoxyethyl]-[1,2,4]triazolo[4,3-a]pyridin-5-yl]methyl 3-hydroxypyrrolidine-1-carboxylate Chemical compound CCN(CC)C1CC(C1)S(=O)(=O)NC(COCc1ccccc1)c1nnc2cccc(COC(=O)N3CCC(O)C3)n12 NVDCCPJZDUJEGP-UHFFFAOYSA-N 0.000 description 1
• MGRSTJZKVXDREM-UHFFFAOYSA-N [3-[1-[[4-(diethylamino)cyclohexyl]sulfonylamino]-2-phenylmethoxyethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl]methyl N-methylcarbamate Chemical compound CCN(CC)C1CCC(CC1)S(=O)(=O)NC(COCc1ccccc1)c1nnc2CC(COC(=O)NC)CCn12 MGRSTJZKVXDREM-UHFFFAOYSA-N 0.000 description 1
• RARCRNFICHQLCM-UHFFFAOYSA-N [3-[1-[[4-(diethylamino)cyclohexyl]sulfonylamino]-2-phenylmethoxyethyl]-[1,2,4]triazolo[4,3-a]pyridin-5-yl]methyl 3-hydroxypyrrolidine-1-carboxylate Chemical compound CCN(CC)C1CCC(CC1)S(=O)(=O)NC(COCc1ccccc1)c1nnc2cccc(COC(=O)N3CCC(O)C3)n12 RARCRNFICHQLCM-UHFFFAOYSA-N 0.000 description 1
• 210000001015 abdomen Anatomy 0.000 description 1
• 238000012084 abdominal surgery Methods 0.000 description 1
• 229940124532 absorption promoter Drugs 0.000 description 1
• 230000001133 acceleration Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 208000004064 acoustic neuroma Diseases 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 230000009056 active transport Effects 0.000 description 1
• 201000011040 acute kidney failure Diseases 0.000 description 1
• 208000012998 acute renal failure Diseases 0.000 description 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
• 238000011360 adjunctive therapy Methods 0.000 description 1
• 239000011543 agarose gel Substances 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
• 125000002947 alkylene group Chemical group 0.000 description 1
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
• CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
• 229940063655 aluminum stearate Drugs 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 125000004103 aminoalkyl group Chemical group 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 238000001949 anaesthesia Methods 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 230000000202 analgesic effect Effects 0.000 description 1
• 239000003957 anion exchange resin Substances 0.000 description 1
• 230000002891 anorexigenic effect Effects 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 239000002220 antihypertensive agent Substances 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 210000000544 articulatio talocruralis Anatomy 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 230000000923 atherogenic effect Effects 0.000 description 1
• 230000003190 augmentative effect Effects 0.000 description 1
• 229960003071 bacitracin Drugs 0.000 description 1
• 229930184125 bacitracin Natural products 0.000 description 1
• CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
• 235000013871 bee wax Nutrition 0.000 description 1
• 239000012166 beeswax Substances 0.000 description 1
• 230000003542 behavioural effect Effects 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• 201000007180 bile duct carcinoma Diseases 0.000 description 1
• 201000001531 bladder carcinoma Diseases 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
• 230000010072 bone remodeling Effects 0.000 description 1
• 230000024279 bone resorption Effects 0.000 description 1
• 239000012888 bovine serum Substances 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• 201000008274 breast adenocarcinoma Diseases 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
• 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
• 230000001275 ca(2+)-mobilization Effects 0.000 description 1
• 230000001612 cachectic effect Effects 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 208000025188 carcinoma of pharynx Diseases 0.000 description 1
• 210000002318 cardia Anatomy 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 230000002612 cardiopulmonary effect Effects 0.000 description 1
• 210000000748 cardiovascular system Anatomy 0.000 description 1
• 239000012876 carrier material Substances 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 235000019438 castor oil Nutrition 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 201000007455 central nervous system cancer Diseases 0.000 description 1
• 208000025997 central nervous system neoplasm Diseases 0.000 description 1
• 210000004289 cerebral ventricle Anatomy 0.000 description 1
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 239000003795 chemical substances by application Substances 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 239000000460 chlorine Substances 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 150000001841 cholesterols Chemical class 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 230000002060 circadian Effects 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 239000008119 colloidal silica Substances 0.000 description 1
• 230000004600 colonic motility Effects 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 230000006957 competitive inhibition Effects 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 208000012696 congenital leptin deficiency Diseases 0.000 description 1
• 230000037011 constitutive activity Effects 0.000 description 1
• 230000008602 contraction Effects 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
• 229960000258 corticotropin Drugs 0.000 description 1
• 239000002537 cosmetic Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 230000001186 cumulative effect Effects 0.000 description 1
• 125000006165 cyclic alkyl group Chemical group 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 229940097362 cyclodextrins Drugs 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 208000002445 cystadenocarcinoma Diseases 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000003412 degenerative effect Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 230000002638 denervation Effects 0.000 description 1
• 238000000326 densiometry Methods 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 238000009795 derivation Methods 0.000 description 1
• 230000001687 destabilization Effects 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 208000033679 diabetic kidney disease Diseases 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 230000003205 diastolic effect Effects 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 210000002249 digestive system Anatomy 0.000 description 1
• 208000018554 digestive system carcinoma Diseases 0.000 description 1
• GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
• 230000003467 diminishing effect Effects 0.000 description 1
• 125000000532 dioxanyl group Chemical group 0.000 description 1
• ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
• 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
• 235000019797 dipotassium phosphate Nutrition 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
• 235000014632 disordered eating Nutrition 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
• 229940043264 dodecyl sulfate Drugs 0.000 description 1
• 230000003291 dopaminomimetic effect Effects 0.000 description 1
• 230000002222 downregulating effect Effects 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 239000003814 drug Substances 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 208000000718 duodenal ulcer Diseases 0.000 description 1
• 210000001198 duodenum Anatomy 0.000 description 1
• 235000005686 eating Nutrition 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 201000011523 endocrine gland cancer Diseases 0.000 description 1
• 210000000750 endocrine system Anatomy 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 229940088598 enzyme Drugs 0.000 description 1
• 208000037828 epithelial carcinoma Diseases 0.000 description 1
• 230000000925 erythroid effect Effects 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 230000008622 extracellular signaling Effects 0.000 description 1
• 230000003031 feeding effect Effects 0.000 description 1
• 239000012894 fetal calf serum Substances 0.000 description 1
• 208000030941 fetal growth restriction Diseases 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 229940012952 fibrinogen Drugs 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
• PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 description 1
• 238000011902 gastrointestinal surgery Methods 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 238000003633 gene expression assay Methods 0.000 description 1
• 229960002518 gentamicin Drugs 0.000 description 1
• 238000009650 gentamicin protection assay Methods 0.000 description 1
• 229940116332 glucose oxidase Drugs 0.000 description 1
• 235000019420 glucose oxidase Nutrition 0.000 description 1
• 238000007446 glucose tolerance test Methods 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
• 229960002449 glycine Drugs 0.000 description 1
• 208000020475 growth hormone-producing pituitary gland neoplasm Diseases 0.000 description 1
• 238000001631 haemodialysis Methods 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 230000003862 health status Effects 0.000 description 1
• 230000004217 heart function Effects 0.000 description 1
• 201000002222 hemangioblastoma Diseases 0.000 description 1
• 230000000322 hemodialysis Effects 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• 125000004475 heteroaralkyl group Chemical group 0.000 description 1
• 125000004447 heteroarylalkenyl group Chemical group 0.000 description 1
• 125000005114 heteroarylalkoxy group Chemical group 0.000 description 1
• 125000005312 heteroarylalkynyl group Chemical group 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 102000056070 human SOD1 Human genes 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 229960000890 hydrocortisone Drugs 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• 229920001600 hydrophobic polymer Polymers 0.000 description 1
• 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
• 201000008980 hyperinsulinism Diseases 0.000 description 1
• 230000002390 hyperplastic effect Effects 0.000 description 1
• 208000008384 ileus Diseases 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 229940102213 injectable suspension Drugs 0.000 description 1
• 230000006362 insulin response pathway Effects 0.000 description 1
• 208000028774 intestinal disease Diseases 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
• 238000000185 intracerebroventricular administration Methods 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 238000007919 intrasynovial administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 108010027047 ipamorelin Proteins 0.000 description 1
• 229950002987 ipamorelin Drugs 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 238000002350 laparotomy Methods 0.000 description 1
• 210000002429 large intestine Anatomy 0.000 description 1
• 239000004816 latex Substances 0.000 description 1
• 229920000126 latex Polymers 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 208000006132 lipodystrophy Diseases 0.000 description 1
• 206010024627 liposarcoma Diseases 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 244000144972 livestock Species 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
• 238000004020 luminiscence type Methods 0.000 description 1
• 201000005296 lung carcinoma Diseases 0.000 description 1
• 230000005980 lung dysfunction Effects 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
• 208000012804 lymphangiosarcoma Diseases 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 239000000391 magnesium silicate Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
• 235000019341 magnesium sulphate Nutrition 0.000 description 1
• 229940099273 magnesium trisilicate Drugs 0.000 description 1
• 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
• 235000019793 magnesium trisilicate Nutrition 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 230000006510 metastatic growth Effects 0.000 description 1
• WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
• ZLADYZHDLCSTJV-UHFFFAOYSA-N methyl n-(2-hydroxyethyl)carbamate Chemical compound COC(=O)NCCO ZLADYZHDLCSTJV-UHFFFAOYSA-N 0.000 description 1
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
• 238000010208 microarray analysis Methods 0.000 description 1
• 238000010232 migration assay Methods 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000036651 mood Effects 0.000 description 1
• 208000001022 morbid obesity Diseases 0.000 description 1
• STUHQDIOZQUPGP-UHFFFAOYSA-N morpholin-4-ium-4-carboxylate Chemical compound OC(=O)N1CCOCC1 STUHQDIOZQUPGP-UHFFFAOYSA-N 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• 208000001611 myxosarcoma Diseases 0.000 description 1
• BMMKGFHYBJRLBH-UHFFFAOYSA-N n-(2-aminoethyl)-n-prop-2-enoylprop-2-enamide Chemical compound NCCN(C(=O)C=C)C(=O)C=C BMMKGFHYBJRLBH-UHFFFAOYSA-N 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 210000003739 neck Anatomy 0.000 description 1
• 208000025189 neoplasm of testis Diseases 0.000 description 1
• 230000008764 nerve damage Effects 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 108010021512 neuromedin U Proteins 0.000 description 1
• 239000002581 neurotoxin Substances 0.000 description 1
• 231100000618 neurotoxin Toxicity 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 230000006959 non-competitive inhibition Effects 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 150000003833 nucleoside derivatives Chemical class 0.000 description 1
• 238000011580 nude mouse model Methods 0.000 description 1
• 238000013116 obese mouse model Methods 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 210000000287 oocyte Anatomy 0.000 description 1
• 108060005714 orexin Proteins 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 230000008816 organ damage Effects 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 210000000963 osteoblast Anatomy 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 230000009996 pancreatic endocrine effect Effects 0.000 description 1
• 210000004923 pancreatic tissue Anatomy 0.000 description 1
• 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
• 201000010198 papillary carcinoma Diseases 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
• 229960001412 pentobarbital Drugs 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 208000027232 peripheral nervous system disease Diseases 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 150000003905 phosphatidylinositols Chemical class 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 229940075930 picrate Drugs 0.000 description 1
• OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
• 208000024724 pineal body neoplasm Diseases 0.000 description 1
• 201000004123 pineal gland cancer Diseases 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
• 229950010765 pivalate Drugs 0.000 description 1
• 239000013612 plasmid Substances 0.000 description 1
• 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 229920000058 polyacrylate Polymers 0.000 description 1
• 125000003367 polycyclic group Chemical group 0.000 description 1
• 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 208000024896 potassium deficiency disease Diseases 0.000 description 1
• 239000004302 potassium sorbate Substances 0.000 description 1
• 235000010241 potassium sorbate Nutrition 0.000 description 1
• 229940069338 potassium sorbate Drugs 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
• 201000001514 prostate carcinoma Diseases 0.000 description 1
• 229950008679 protamine sulfate Drugs 0.000 description 1
• 230000004845 protein aggregation Effects 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 230000003331 prothrombotic effect Effects 0.000 description 1
• 230000009325 pulmonary function Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 210000001187 pylorus Anatomy 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 238000005956 quaternization reaction Methods 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 239000002287 radioligand Substances 0.000 description 1
• 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
• 206010038038 rectal cancer Diseases 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 201000001275 rectum cancer Diseases 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 102220020162 rs397508045 Human genes 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 238000009738 saturating Methods 0.000 description 1
• 201000000980 schizophrenia Diseases 0.000 description 1
• 210000003497 sciatic nerve Anatomy 0.000 description 1
• CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
• 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
• 230000009991 second messenger activation Effects 0.000 description 1
• 238000003572 second messenger assay Methods 0.000 description 1
• 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 230000037075 skin appearance Effects 0.000 description 1
• 230000004215 skin function Effects 0.000 description 1
• 210000003625 skull Anatomy 0.000 description 1
• 201000002859 sleep apnea Diseases 0.000 description 1
• 208000022925 sleep disturbance Diseases 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 101150017120 sod gene Proteins 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000006104 solid solution Substances 0.000 description 1
• 230000003381 solubilizing effect Effects 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 125000006850 spacer group Chemical group 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 208000023516 stroke disease Diseases 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
• 125000000565 sulfonamide group Chemical group 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 238000011477 surgical intervention Methods 0.000 description 1
• 201000010965 sweat gland carcinoma Diseases 0.000 description 1
• 206010042863 synovial sarcoma Diseases 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 230000002381 testicular Effects 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 230000002992 thymic effect Effects 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 208000030829 thyroid gland adenocarcinoma Diseases 0.000 description 1
• 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 230000007306 turnover Effects 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 230000036269 ulceration Effects 0.000 description 1
• ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
• 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
• 210000002229 urogenital system Anatomy 0.000 description 1
• 238000002255 vaccination Methods 0.000 description 1
• 210000001186 vagus nerve Anatomy 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 208000016261 weight loss Diseases 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 210000002268 wool Anatomy 0.000 description 1
• 229910052727 yttrium Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• 150000003751 zinc Chemical class 0.000 description 1
• GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1